Compounding Pharmacy Market
Compounding Pharmacy Market by Product (Oral, Topical, Parenteral), Type (Ingredient Alteration, Dosage Alteration), Therapeutic Application (Pain Management, HRT, Dermatology), Sterility (Sterile), End User, Competition, Region - Global Forecast to 2031
COMPOUNDING PHARMACY MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global compounding pharmacy market is projected to grow from USD 15.48 billion in 2026 to USD 21.01 billion by 2031, at a CAGR of 6.3% during the forecast period. The market was valued at USD 14.34 billion in 2025. A compounding pharmacy is a practice in which a licensed pharmacist combines, mixes, or alters drug ingredients to create a medication tailored to an individual patient's needs. Its market growth is fueled by persistent drug shortages in North America and Europe and a continued supply gap for GLP-1 drugs, to enhance compounding pharmacy revenues.
KEY TAKEAWAYS
-
MARKET SNAPSHOT:
Base Year Market Size (2025): USD 14.34 Billion
Current Market Size (2026): USD 15.48 Billion
Forecast Market Size (2031): USD 21.01 Billion
CAGR (2026–2031): 6.3% -
SEGMENT LEADERSHIP:
Regional Leader: North America accounted for approximately 43.5% of the compounding pharmacy market in 2025.
Product Leader: Oral drugs accounted for approximately 33.4% of the market in 2025.
Fastest-Growing Compounding Type: Pharmaceutical dosage alteration is projected to grow at a CAGR of 7.1% during the forecast period.
Therapeutic Application Leader: Pain management accounted for the largest market share in 2025.
End User Leader: Adult patients dominated the market in 2025, with a share of 58.3%. -
MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
Baxter (US), B. Braun (Germany), and Fagron (Netherlands) were identified as key players in the global compounding pharmacy market, given their strong market share and product footprint.
Companies such as Innovation Compounding Pharmacy (US), Medios AG (Germany), and Wells Pharma (US) have distinguished themselves among startups and SMEs by establishing strong footholds in specialized niches, underscoring their potential as emerging market leaders.
The compounding pharmacy market is expected to grow strongly over the coming decade, driven by the implementation of USP standards, which increases the need for compliant compounding practices, along with a growing focus on ready-to-administer (RTA) products and standardized dosing. Compounding pharmacies play an increasingly important role in healthcare by preparing customized medications to meet patient needs that commercially available products cannot adequately address. Rising demand for personalized therapies, treatment options for rare conditions, and medication alternatives during drug shortages is further supporting market expansion. The ability to customize dosage forms, strengths, and formulations positions compounding pharmacies as an important component of patient-centric care, with applications expanding across hospitals, specialty clinics, and community healthcare settings.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
Compounding pharmacies’ business is being shaped by changing patient and healthcare provider trends. The market has seen major shifts that are likely to speed up during the forecast period. These include the growing prevalence of chronic diseases, increased use of personalized medicines with tailored dosage forms, rising demand for sterile compounding and biologics support, and growing interest in weight management and hormone replacement therapies. These short- and long-term trends are expected to alter demand patterns across hospitals, specialty clinics, and retail pharmacies, creating growth opportunities for compounding pharmacies and their suppliers.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Persistent drug shortages in North America and Europe
-
Full enforcement of USP standards boosts demand for compliant compounding services
Level
-
Resolution of GLP-1 shortages reduces reliance on compounded alternatives
-
Stricter FDA oversight & insanitary conditions enforcement
Level
-
Radiopharmaceutical compounding standardization
-
Expansion of hospital outsourcing into anesthesia, critical care, ophthalmic, and chemo-adjuncts
Level
-
Capacity bottlenecks in API, excipient supply, and CCI/testing
-
Limited quality-system maturity and gaps in stability/BUD evidence generation
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Persistent drug shortages in North America and Europe
Ongoing drug shortages across North America and Europe are driving growth in the compounding pharmacy market. As conventional manufacturers struggle to meet demand, healthcare providers increasingly turn to compounding pharmacies for customized, high-quality medications, particularly for adult, pediatric, and geriatric patients with specialized therapeutic needs.
Restraint: Resolution of GLP-1 shortages reduces reliance on compounded alternatives
Resolving GLP-1 drug shortages is expected to reduce demand for compounded alternatives as commercially available products become more accessible. As branded manufacturers increasingly meet market needs, healthcare providers and patients may need fewer customized formulations, particularly for adult, pediatric, and geriatric populations.
Opportunity: Radiopharmaceutical compounding standardization
Greater standardization of radiopharmaceutical compounding can drive market growth by supporting consistent production and quality across diverse patient populations. Improved standards can enhance safety, effectiveness, and regulatory compliance while enabling pharmacies to efficiently prepare radiopharmaceuticals for adult, pediatric, and geriatric patients across hospitals, specialty clinics, and nuclear medicine facilities.
Challenge: Capacity bottlenecks in API, excipient supply, and CCI/testing
Capacity constraints involving APIs, excipients, and CDMO services remain a key challenge for the compounding pharmacy market. Limited availability of high-quality raw materials and manufacturing capacity can restrict the production of customized medications, particularly for adult, pediatric, and geriatric patients, potentially affecting service reliability and market expansion.
COMPOUNDING PHARMACY MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Provides sterile and non-sterile compounding services, including ready-to-dispense and ready-to-administer personalized medicines for pharmacies, hospitals, and clinics | Its compounding operations support customized strengths, dosage forms, ingredient requirements, and therapies where commercially available medicines may be unsuitable or unavailable. | Enables healthcare providers to address patient-specific medication requirements, drug shortages, discontinued products, allergies, and dosage-form limitations while outsourcing complex sterile and non-sterile compounding activities. |
 |
Operates both a 503A compounding pharmacy for patient-specific prescriptions and an FDA-registered 503B outsourcing facility for office-use medications | Its portfolio includes compounded preparations across multiple therapeutic areas and dosage forms, supported by sterile batch testing and cGMP processes at the 503B facility. | Expands access to individualized medicines and multiple strengths and dosage forms while enabling healthcare providers to procure larger-scale compounded products from a regulated outsourcing facility. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The compounding pharmacy ecosystem involves a network of interconnected stakeholders, including raw material suppliers, compounding pharmacies, contract compounding organizations (CCOs), distributors, and end users. Raw material suppliers provide key inputs such as active pharmaceutical ingredients (APIs), excipients, sterile and non-sterile bases, and specialized chemicals required for compounding operations. Compounding pharmacies use these materials, along with specialized formulations and compounding technologies, to prepare patient-specific medications in various dosage forms, including oral, topical, injectable, and parenteral formulations. CCOs and specialized service providers support manufacturing scale-up, quality control, regulatory compliance, and operations. Distributors and supply partners enable the efficient movement of compounded medications to end users, including pediatric, adult, and geriatric patients. This interconnected supply chain supports operational efficiency, facilitates personalized treatment solutions, and contributes to the broader adoption of compounded medications across multiple therapeutic applications.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Compounding Pharmacy Market, By Product
In 2025, oral drugs held the largest share of the compounding pharmacy market because customization of dosage, flavor, and release profiles improves patient adherence. Growing chronic disease prevalence and advances in formulation technologies also support market growth.
Compounding Pharmacy Market, By Compounding Type
In 2025, pharmaceutical dosage alteration accounted for the largest share by compounding type, driven by the need for personalized dosing, patient-specific formulations, improved adherence, and flexibility across pediatric, adult, and geriatric populations.
Compounding Pharmacy Market, By Therapeutic Application
In 2025, pain management accounted for the largest share by therapeutic area in the compounding pharmacy market, driven by rising chronic pain prevalence, growing demand for personalized therapies, and the increasing adoption of customized topical and oral formulations.
Compounding Pharmacy Market, By Sterility
In 2025, sterile compounding dominated the compounding pharmacy market, driven by rising demand for injectable medications, parenteral nutrition, and advanced biologic therapies.
Compounding Pharmacy Market, By End User
The adults segment held the largest share by end user in 2025, driven by the rising prevalence of chronic conditions among adults, which require tailored treatment options.
REGION
Asia Pacific to be fastest-growing region in market during forecast period
The Asia Pacific region is the fastest-growing market for compounding pharmacies, driven by rising healthcare awareness, increasing prevalence of chronic diseases, expanding geriatric and pediatric populations, and growing adoption of personalized medications. Supportive government initiatives, improved healthcare infrastructure, and a strong workforce of skilled pharmacists further fuel growth in the region.
COMPOUNDING PHARMACY MARKET: COMPANY EVALUATION MATRIX
In the global compounding pharmacy market, Baxter is the leading player, supported by its large-scale manufacturing capabilities, broad portfolio of compounded and ready-to-administer medications, and established presence across hospitals and healthcare facilities. Its extensive production infrastructure, quality-focused operations, and well-established distribution network strengthen its market position and support growing demand for standardized and patient-specific compounded medications. Nephron Pharmaceuticals is an emerging player, driven by its strong capabilities in sterile pharmaceutical manufacturing, ready-to-administer products, and expanding supply to hospitals and healthcare providers. Its focus on sterile drug production, manufacturing capacity expansion, and quality-driven pharmaceutical solutions positions the company to benefit from increasing demand for compounded and customized medications.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Baxter (US)
- Empower Pharmacy (US)
- Fagron NV (Netherlands)
- B. Braun Melsungen (Germany)
- QuVa Pharma (US)
- SCA Pharma (US)
- Nephron Pharmaceutical (US)
- Leiters Health (US)
- Pharmaxo (UK)
- Icon Group (Australia)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 14.34 Billion |
| Market Forecast in 2026 (Value) | USD 15.48 Billion |
| Market Forecast in 2031 (Value) | USD 21.01 Billion |
| Growth Rate | Growth Rate of 6.3% from 2026–2031 |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
WHAT IS IN IT FOR YOU: COMPOUNDING PHARMACY MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Formulation Insights | Evaluation of dosage forms, including topical, oral, and injectable formulations, along with excipient compatibility | Supports pharmacists in optimizing formulation stability, bioavailability, and patient compliance |
| Regulatory & Compliance Overview | Review of FDA 503A/503B requirements, USP standards, and applicable state-level regulations | Facilitates regulatory compliance and improves preparedness for audits and inspections |
| Technology Comparison | Assessment of compounding and commercial alternatives based on cost, efficacy, accessibility, and suitability | Enables informed decisions regarding service offerings, technology adoption, and pricing strategies |
RECENT DEVELOPMENTS
- August 2026 : Baxter announced a new compounding department at its Thetford facility in the UK. The facility incorporates semi-automated compounding processes to increase productivity, reduce manual operations, and expand capacity for compounded chemotherapy and antibiotic preparations supplied to patients in hospitals and home settings.
- February 2025 : Empower Pharmacy introduced Sermorelin Acetate ODT, a new compounded, non-injectable formulation offered alongside its existing sermorelin injectable formulation.
- February 2024 : Empower Pharma acquired Eugia US Manufacturing LLC's manufacturing facility in East Windsor, New Jersey. This acquisition expands Empower Pharma's sterile development and bulk manufacturing capabilities for personalized compounded medicine.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This study involved four major activities to estimate the current size of the compounding pharmacy market. We conducted exhaustive secondary research to gather information on the market, its peer markets, and its parent market. The team then validated these findings, assumptions, and sizing with industry experts across the value chain through primary research. We used both top-down and bottom-up approaches to estimate total market size. We then used data triangulation to estimate market size by segment and subsegment.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the compounding pharmacy market. The secondary sources used for this study include US Food and Drug Administration (FDA), American Pharmacists Association (APhA), International Academy of Compounding Pharmacists (IACP), National Community Pharmacists Association (NCPA), Parenteral Drug Association (PDA), American Society of Health-System Pharmacists (ASHP), Pharmacy Compounding Accreditation Board (PCAB), European Directorate for the Quality of Medicines & HealthCare (EDQM), European Medicines Agency (EMA), International Pharmaceutical Federation (FIP), Journal of Compounding & Specialty Pharmacy (JCSP), National Center for Biotechnology Information (NCBI), Pharmaceutical Research and Manufacturers of America (PhRMA), Pharma & Biopharma Outsourcing Association (PBOA), and World Journal of Pharmaceutical Research (WJPR). Secondary sources also include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; trade, business, and professional associations; and MarketsandMarkets Analysis. These sources were also used to obtain key information on major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
We conducted in-depth interviews with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. We interviewed primary sources from both the supply and demand sides of the market to gather qualitative and quantitative data. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
We estimated the global size of the compounding pharmacy market using multiple approaches. We used a detailed market estimation approach to estimate and validate the market value and other dependent submarkets. We also used these methods extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following.
Compounding Pharmacy Market: Top-Down and Bottom-Up Approach
Data Triangulation
After estimating the market size using the process described above, we divided the total market into several segments and subsegments. To complete the overall market analysis and obtain precise statistics for all segments and subsegments, we used data triangulation and market breakdown methods where applicable. We triangulated the data by examining factors and trends from both the demand and supply sides.
Market Definition
A compounding pharmacy is a specialized practice in which a licensed pharmacist combines, mixes, or alters raw drug ingredients to formulate customized medications tailored to individual patients' unique health needs. This process allows pharmacists to create pharmaceutical products in various forms, such as liquids, creams, gels, or capsules, and can be vital for patients with specific allergies, intolerances, or those needing dosages not commercially available. Compounding pharmacists often work closely with healthcare providers to develop formulas that address particular medical conditions, ensuring that each preparation is safe, effective, and personalized to optimize patient care. Additionally, compounding pharmacies adhere to stringent regulatory standards to maintain the integrity and quality of the medications they produce.
Key Stakeholders
- Pharmaceutical & Biotechnology Companies
- Compounding Pharmacies
- Research & Consulting Firms
- Academic Medical Centers
- Government Regulatory & Research Organizations
- Quality Assurance & Accreditation Bodies
- Clinical Research Institutes
Report Objectives
- To define, describe, and forecast the compounding pharmacy market based on product, compounding type, therapeutic application, sterility, end user, and region
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall compounding pharmacy market
- To analyze opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), and the Middle East & Africa (GCC Countries and the Rest of Middle East & Africa)
- To profile the key players and analyze their market share and core competencies
- To analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available customizations:
With the given market data, MarketsandMarkets offers customization as per the company’s specific needs. The following options are available for the report:
Geographical Analysis
- A further breakdown of the Rest of Asia Pacific compounding pharmacy market into countries
- A further breakdown of the Rest of Europe compounding pharmacy market into countries
- A further breakdown of the Rest of Latin America compounding pharmacy market into countries
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Compounding Pharmacy Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Companywww.sfihealth.com/
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Companywww.qualicaps.com/
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnosticsimaging.bracco.com/us-en
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.www.3m.com/3M/en_US/health-information-systems-us
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
- Canada Compounding Pharmacy Market
- US Compounding Pharmacy Market
- Germany Compounding Pharmacy Market
- UK Compounding Pharmacy Market
- France Compounding Pharmacy Market
- Italy Compounding Pharmacy Market
- Spain Compounding Pharmacy Market
- China Compounding Pharmacy Market
- Japan Compounding Pharmacy Market
- India Compounding Pharmacy Market
- Australia Compounding Pharmacy Market
- South Korea Compounding Pharmacy Market
- Brazil Compounding Pharmacy Market
- Mexico Compounding Pharmacy Market
- Rest Of Europe Compounding Pharmacy Market
- Rest Of Asia Pacific Compounding Pharmacy Market
- Rest Of Latin America Compounding Pharmacy Market
Growth opportunities and latent adjacency in Compounding Pharmacy Market